Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.

Journal Article (Journal Article)

BACKGROUND: Patients with thick (Breslow>4 mm) primary melanoma and/or regional nodal metastasis have a high risk of tumor recurrence. High-dose adjuvant interferon (IFN) alfa-2b offers/=50% risk of recurrence/disease-related mortality and offered IFN. Telephone surveys delineated reasons behind patients' decisions to accept IFN. RESULTS: Acceptors, 60 of 135 (45%), decided to take IFN alfa-2b whereas 75 of 135 (55%) declined. Being female (OR, 2.4; 95% CI, 1.17-5.03; p=.017) and positive SLN status (OR, 2.2; 95% CI, 1.01-4.97; p=.048) were strongly associated with patients who chose IFN. Acceptors of IFN were younger, more influenced by physicians, and less affected by depression and side effect profile (p<.05 for all). Decliners were more concerned by strained relationships with family and social life (p<.05). CONCLUSIONS: Gender and positive SLN were predictive of high-risk melanoma patients' acceptance of IFN treatment. Physician insight into melanoma patients' therapeutic decision-making process can guide patients through this difficult disease.

Full Text

Duke Authors

Cited Authors

  • Bramlette, TB; Lawson, DH; Washington, CV; Veledar, E; Johns, BR; Brisman, SF; Abramova, L; Chen, SC

Published Date

  • January 1, 2007

Published In

Volume / Issue

  • 33 / 1

Start / End Page

  • 11 - 16

PubMed ID

  • 17214673

International Standard Serial Number (ISSN)

  • 1076-0512

Digital Object Identifier (DOI)

  • 10.1111/j.1524-4725.2007.33001.x


  • eng

Conference Location

  • United States